189 related articles for article (PubMed ID: 20167479)
1. SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors.
Desai D; Salli U; Vrana KE; Amin S
Bioorg Med Chem Lett; 2010 Mar; 20(6):2044-7. PubMed ID: 20167479
[TBL] [Abstract][Full Text] [Related]
2. Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells.
Karelia N; Desai D; Hengst JA; Amin S; Rudrabhatla SV; Yun J
Bioorg Med Chem Lett; 2010 Nov; 20(22):6816-9. PubMed ID: 20855208
[TBL] [Abstract][Full Text] [Related]
3. Selenium-Based Novel Epigenetic Regulators Offer Effective Chemotherapeutic Alternative with Wider Safety Margins in Experimental Colorectal Cancer.
Ghanghas P; Sharma M; Desai D; Raza K; Bhalla A; Kumar P; Narula D; Amin S; Sanyal SN; Kaushal N
Biol Trace Elem Res; 2022 Feb; 200(2):635-646. PubMed ID: 33677818
[TBL] [Abstract][Full Text] [Related]
4. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
5. Phosphorus containing analogues of SAHA as inhibitors of HDACs.
Pun MD; Wu HH; Olatunji FP; Kesic BN; Peters JW; Berkman CE
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1315-1319. PubMed ID: 35514164
[TBL] [Abstract][Full Text] [Related]
6. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
[TBL] [Abstract][Full Text] [Related]
7. In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC).
Tambunan US; Bramantya N; Parikesit AA
BMC Bioinformatics; 2011; 12 Suppl 13(Suppl 13):S23. PubMed ID: 22373132
[TBL] [Abstract][Full Text] [Related]
8. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
9. Novel Suberoylanilide Hydroxamic Acid Analogs Inhibit Angiogenesis and Induce Apoptosis in Breast Cancer Cells.
Moku G; Vangala S; Yakati V; Gali CC; Saha S; Madamsetty VS; Vyas A
Anticancer Agents Med Chem; 2022; 22(5):914-925. PubMed ID: 34488592
[TBL] [Abstract][Full Text] [Related]
10. SelSA-1, a novel HDAC inhibitor demonstrates enhanced chemotherapeutic potential by redox modulation.
Garg A; Desai D; Bhalla A; Thakur S; Rastogi P; Kaushal N
Sci Rep; 2023 Jun; 13(1):9301. PubMed ID: 37291249
[TBL] [Abstract][Full Text] [Related]
11. Thiol-based SAHA analogues as potent histone deacetylase inhibitors.
Suzuki T; Kouketsu A; Matsuura A; Kohara A; Ninomiya S; Kohda K; Miyata N
Bioorg Med Chem Lett; 2004 Jun; 14(12):3313-7. PubMed ID: 15149697
[TBL] [Abstract][Full Text] [Related]
12. Histone Deacetylase Inhibitors Relax Mouse Aorta Partly through Their Inhibitory Action on L-Type Ca
Zheng C; Zhong M; Qi Z; Shen F; Zhao Q; Wu L; Huang Y; Tsang SY; Yao X
J Pharmacol Exp Ther; 2017 Nov; 363(2):211-220. PubMed ID: 28860353
[TBL] [Abstract][Full Text] [Related]
13. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
You BR; Han BR; Park WH
Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
[TBL] [Abstract][Full Text] [Related]
14. MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells.
Imesch P; Dedes KJ; Furlato M; Fink D; Fedier A
Int J Oncol; 2009 Sep; 35(3):631-40. PubMed ID: 19639184
[TBL] [Abstract][Full Text] [Related]
15. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.
Codd R; Braich N; Liu J; Soe CZ; Pakchung AA
Int J Biochem Cell Biol; 2009 Apr; 41(4):736-9. PubMed ID: 18725319
[TBL] [Abstract][Full Text] [Related]
16. Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors.
Belvedere S; Witter DJ; Yan J; Secrist JP; Richon V; Miller TA
Bioorg Med Chem Lett; 2007 Jul; 17(14):3969-71. PubMed ID: 17507219
[TBL] [Abstract][Full Text] [Related]
17. Deacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex.
Smith KT; Martin-Brown SA; Florens L; Washburn MP; Workman JL
Chem Biol; 2010 Jan; 17(1):65-74. PubMed ID: 20142042
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors trichostatin A and vorinostat inhibit TGFβ2-induced lens epithelial-to-mesenchymal cell transition.
Xie L; Santhoshkumar P; Reneker LW; Sharma KK
Invest Ophthalmol Vis Sci; 2014 Jul; 55(8):4731-40. PubMed ID: 24994865
[TBL] [Abstract][Full Text] [Related]
19. Novel Hydroxamic Acids Incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)- 3-substituted-2-oxoindolines: Synthesis, Biological Evaluation and SAR Analysis.
Dung DTM; Huan NV; Cam DM; Hieu DC; Hai PT; Huong LT; Kim J; Choi JE; Kang JS; Han SB; Nam NH
Med Chem; 2018; 14(8):831-850. PubMed ID: 29807520
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
Kulp SK; Chen CS; Wang DS; Chen CY; Chen CS
Clin Cancer Res; 2006 Sep; 12(17):5199-206. PubMed ID: 16951239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
